Angion Biomedica Corp expected to post a loss of 36 cents a share - Earnings Preview
Brief: Elicio Therapeutics Inc Files To Withdraw IPO Plans - SEC Filing
Brief: Elicio Therapeutics Publishes Preclinical Data On ELI-005
Angion Biomedica Corp reports results for the quarter ended in June - Earnings Summary
Brief: Angion Provides Q2 2022 Financial Results
Angion Biomedica Corp expected to post a loss of 46 cents a share - Earnings Preview
Brief: Angion Biomedica - On July 20,, Angion Committed To And Commenced A Reduction In Force That Will Impact Majority Of Angion's Current 37 Employees
Brief: Angion Announces Process To Explore Strategic Alternatives For Enhancing And Preserving Shareholder Value
Brief: Elicio Therapeutics Presents Preclinical Data On Its Lymph Node-Targeted Sars-COV-2 Amphiphile Vaccine, Eli-005
U.S. STOCKS ON THE MOVE-Walgreens, Enjoy Technology, Aura Biosciences, Goldman
U.S. STOCKS ON THE MOVE-Alphabet, Boeing, iRobot, Enjoy Tech
U.S. STOCKS ON THE MOVE-Spirit Airlines, Aspen Aerogels, Adagene
U.S. STOCKS ON THE MOVE-Tesla, Walgreens, Boeing, crypto-related stocks
Angion ending kidney drug trial threatens lung disease therapy program- analysts
Angion Biomedica falls as kidney disease drug trial discontinued
Brief: Angion Biomedica- Expects To Report Cash And Cash Equivalents As Of June 30, 2022, Totaling Over $60 Million When It Reports Its Q2 Earnings In August 2022
Brief: Angion Announces Discontinuation Of Phase 2 Trial Of ANG-3070 In Patients With Primary Proteinuric Kidney Disease
NASDAQ RESUMED AT 04:35 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:16 PM